Zemplenyi, Antal
Leonard, Jim
DiStefano, Michael J.
Anderson, Kelly E.
Wright, Garth C.
Mendola, Nicholas D.
Nair, Kavita
McQueen, R. Brett
Funding for this research was provided by:
Colorado Department of Health Care Policy & Financing
Article History
Accepted: 2 November 2023
First Online: 21 November 2023
Declarations
:
: The University of Colorado is funded by the Department of Health Care Policy & Financing for the assessment of value-based contracts. Dr. Zemplenyi authored this manuscript during his Fulbright Visiting Scholarship at the University of Colorado Anschutz Medical Campus.
: Dr. Leonard is affiliated with the Colorado Department of Health Care Policy & Financing. The authors have disclosed no conflicts of interest concerning the research, authorship, or publication of this article. None of the authors are affiliated with or hold financial interests in the manufacturers of the gene therapies investigated in this study. The views expressed in this article represent the opinions of the authors and do not necessarily reflect those of their respective employers.
: All data analyzed during this work are from the Colorado Department of Health Care Policy & Financing. The data are not publicly available. The model used during this work was developed by the University of Colorado under a contract with the Colorado Department of Health Care Policy & Financing.
: The study was declared exempt by the Colorado Multiple Institutional Review Board (no. 23-1401).
: AZ, BM, MD, KA, and KN contributed to the study conception and design. Material preparation, data collection and analysis were performed by Garth Wright, NM, and AZ. The first draft of the manuscript was written by AZ and BM and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.